Truist Lowers Neurocrine Biosciences, Inc.’s (NBIX) PT Following 2026 Outlook Update

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is among the 7 Oversold Pharma Stocks to Buy Now. Truist Lowers Neurocrine Biosciences, Inc.'s (NBIX) PT Following 2026 Outlook Update Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is one of the most oversold stocks. TheFly reported on February 17 that Truist reduced its price target on NBIX to $140 from $169 and maintained a Buy rating on the stock. The increase came after management's 2026 projection, and the company's fourth-quarter results were included in the ...